Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
195 hedge funds and large institutions have $2.18B invested in Global Blood Therapeutics, Inc. in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 77 increasing their positions, 65 reducing their positions, and 34 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 65
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
4% less funds holding
Funds holding: 204 → 195 (-9)
9% less capital invested
Capital invested by funds: $2.4B → $2.18B (-$220M)
14% less call options, than puts
Call options by funds: $13.8M | Put options by funds: $16M
21% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$39.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$28.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$27.7M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$25.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$43.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$43.1M |
| 3 |
Goldman Sachs
New York
|
-$34M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$32.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$29.6M |
GBT Hedge Fund Activity: Q2 2022 in Review
195 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2022, worth a combined $2.18B — down 9.1% from $2.4B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of GBT and 27 opened new positions — a net loss of 7 holders — while 65 trimmed existing stakes and 77 added.
The largest buyer was Deep Track Capital, adding an estimated $39.3M. The largest seller was Logos Global Management, exiting entirely with an estimated $43.3M sold.
- 195 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2022, down from 204 in Q1 2022.
- Funds reported $2.18B of Global Blood Therapeutics, Inc. stock for Q2 2022, down 9.1% quarter-over-quarter.
- 27 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2022 and 34 closed out, a net change of -7 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q2 2022 was Deep Track Capital, an estimated $39.3M added.
- The largest Global Blood Therapeutics, Inc. seller in Q2 2022 was Logos Global Management, an estimated $43.3M sold.
Based on aggregated 13F filings for Q2 2022.